AIMS SIG - Open-Source Lunch Bites
Our monthly webinar series allows attendees to gain practical knowledge and skills in open-source coding and tools, with a focus on applications in the pharmaceutical industry.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013
Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012
Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA
Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.